Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Net Cash Flow: 2010-2025

Historic Net Cash Flow for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to $5.1 million.

  • Anika Therapeutics' Net Cash Flow rose 747.91% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 million, marking a year-over-year increase of 47.89%. This contributed to the annual value of -$15.7 million for FY2024, which is 15.67% down from last year.
  • Latest data reveals that Anika Therapeutics reported Net Cash Flow of $5.1 million as of Q3 2025, which was up 1,033.52% from -$549,000 recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Net Cash Flow ranged from a high of $5.6 million in Q3 2023 and a low of -$14.7 million during Q2 2023.
  • Moreover, its 3-year median value for Net Cash Flow was -$3.9 million (2025), whereas its average is -$2.6 million.
  • In the last 5 years, Anika Therapeutics' Net Cash Flow slumped by 1,433.30% in 2023 and then surged by 747.91% in 2025.
  • Anika Therapeutics' Net Cash Flow (Quarterly) stood at $3.3 million in 2021, then plummeted by 141.95% to -$1.4 million in 2022, then soared by 254.96% to $2.1 million in 2023, then plummeted by 337.34% to -$5.1 million in 2024, then spiked by 747.91% to $5.1 million in 2025.
  • Its Net Cash Flow was $5.1 million in Q3 2025, compared to -$549,000 in Q2 2025 and -$3.9 million in Q1 2025.